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Background: In recent years, heart surgery has been used more frequently to treat
diseases that are not primarily of cardiac origin. This is the case for intracardiac
extension of infradiaphragmatic tumors, such as renal cell carcinoma, Wilms tumor,
uterine tumors, and adrenal tumors, which require radical surgery associated with
cavoatrial thrombectomy.
Methods: From April 1987 to April 2001, 13 patients with an infradiaphragmatic
tumor with thrombosis of the vena cava, the right atrium, or both underwent surgical
resection with cardiopulmonary bypass, arrested circulation, and profound hypo-
thermia.
Results: The in-hospital mortality was 0%. The postoperative complications were
respiratory failure (1 patient) and a redo operation for bleeding (1 patient). After a
mean follow-up time of 33.9 months, 8 (61.5%) patients were alive.
Conclusions: The use of extracorporeal circulation and deep circulatory arrest
provide an optimal technique for removing the tumor thrombus in a bloodless field,
even in the presence of metastatic disease, and has good early and long-term results.
Renal and adrenal tumors might involve the inferior vena cava(IVC), with an intraluminal thrombotic extension in 5% to 15% ofall cases and with right atrium (RA) involvement in 1% of cases.Renal cell cancer (RCC) represents 1% to 3% of all visceralcancers and 85% to 90% of malignant kidney tumors and is mostfrequently responsible for this phenomenon (4%-10% of all pa-
tients).1-3 In this kind of pathology, the only available therapy is surgical interven-
tion because conventional antineoplastic therapy alone (radiotherapy and chemo-
therapy) is not useful. It is now accepted that neoplastic extension into the IVC is
not a prognostically determining factor.4 With no perinephric fat or lymph nodal
involvement, it has been observed that the patients who undergo tumor excision with
a radical nephrectomy and IVC thrombectomy have an overall and cancer-specific
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5-year survival of 30% to 72%, with an operative mortality
of 2.7% to 13% and an immediate palliation of symptoms of
obstructive tumors.5-13 The aim of surgical therapy is the
radical removal of neoplastic tissue, including the thrombus
in the IVC, the adjacent lymphatic structures, and, eventu-
ally, the involved caval wall, as well as caval wall recon-
struction. There have been several surgical techniques pro-
posed depending on the proximal extension of the tumor
thrombus. Usually, in type I and II disease (Figure 1) the
tumor excision can be safely achieved by means of simple
proximal and distal control of the IVC. In type III and IV
disease the exposure and isolation of the IVC are more
extensive, requiring liver mobilization with or without the
use of cardiopulmonary bypass (CPB) and, in some circum-
stances, deep hypothermic circulatory arrest (DHCA). We
treated patients with type III and IV disease with CPB and
DHCA.
Materials and Methods
From April 1987 to April 2001, 13 consecutive patients with IVC,
RA, or both types of tumor extension were operated on at the
Department of Cardiovascular Surgery of the University of Bolo-
gna. Seven of these patients had type IV disease, and 6 had type III
disease. There were 9 (69%) male and 4 (31%) female patients.
Mean age was 51.2  21.2 years (minimum, 10 years; maximum,
74 years). Ten (76.9%) patients had RCC, 1 (7.7%) had Wilms
tumor, and 2 (15.4) had adrenal carcinoma. Distant metastases
were identified preoperatively in 4 (30.7%) patients, and lymph
node metastases were found in 5 (38.5%) patients. The first 5
patients were studied preoperatively by using total body computed
tomography scanning and echocardiography; the other 8 patients
were studied with echocardiography and magnetic resonance im-
aging, which is presently the diagnostic test of choice. Patient
characteristics are shown in Table 1. Data are expressed as means
with 1 SD.
All tumors were exposed through a median sternotomy by
using a Chevron incision (Figure 2). After exploration of the
abdomen, a nephrectomy or an adrenalectomy was performed,
being careful not to manipulate the IVC or the RA. Then we
performed a division of the diaphragmatic suspensory ligaments of
the liver, which allowed for increased mobility of the organ, to
expose better the anterior wall of the IVC. After administration of
heparin (3 mg/kg), CPB was instituted by means of aortic cannu-
lation of the ascending aorta and a single short, basket-like venous
cannula. Cooling was continued to maintain a nasopharyngeal
temperature of 18°C. Before the beginning of circulatory arrest,
thiopental (5 mg/kg), mannitol (250 mL at 18%), and methylpred-
nisolone (1 g) were administered to protect the brain and vital
organs during arrest. Immediately before circulatory arrest, the
ascending aorta was crossclamped, and crystalloid cardioplegia
was administered for myocardial protection. After removal of the
atrial cannula, the RA was opened near the orifice of the IVC;
attention was then directed to the IVC, which was entered near the
orifice of the renal vein. The bloodless field allowed for complete
intravascular thrombus extirpation. When the vena caval recon-
struction was accomplished by means of direct suturing, the
2-stage venous cannula was reinserted into the RA, and the patient
was rewarmed.
Results
Either a radical nephrectomy or an adrenalectomy with a
tumor thrombectomy was performed in all patients. There
were no in-hospital deaths. The mean stay in the intensive
care unit was 2.1  2 days (minimum, 1 day; maximum, 7
Figure 1. The 4 stages of cavoatrial tumor thrombus.
Figure 2. The Chevron incision and sternotomy exposing the
IVC.
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days). Five thousand international units of nadroparin was
administered to all patients. Two patients experienced peri-
operative complications: respiratory failure in 1 patient (re-
quiring ventilatory support for 6 days) and a redo operation
for bleeding in 1 patient. Hospital stay averaged 16  2.5
days (range, 14-19 days). The mean follow-up time was
33.9 months (minimum, 4 months; maximum 120 months).
There were 5 (38.5%) late deaths: 4 were caused by rapid
progression of the disease (1 patient who had brain metas-
tasis at the time of the operation died 6 months after the
operation, 1 patient died 5 months later, 1 patient who had
lymph node metastases at the time of the operation died 10
months later, and the fourth patient died 2 years after the
operation), and 1 patient died because of a stroke 2 months
after the surgical treatment. Eight (61.5%) patients are still
alive, with an average postoperative time of 33.9 months; 3
have metastases (lung, n  2; liver, n  1), and 1 one
patient had a rethrombosis of the IVC (type I) 3 months
after the operation, without surgical indication. The latter
patient had a complete resection of tumor; at follow-up he
was asymptomatic, and the IVC was thrombosed by blood
clots rather than tumor thrombus. All patients underwent
chemotherapy or radiation therapy combined with the sur-
gical intervention, and the patient with Wilms tumor under-
went preoperative chemotherapy to shrink the tumor.
Discussion
The most frequent causes of cavoatrial tumor thrombus are
RCC, adrenal carcinoma, liver carcinoma, uterine carci-
noma, and Wilms tumor.3 In 1913, Berg4 described ne-
phrectomy and vena caval thrombectomy for RCC that
extended into the IVC. Since this report, radical tumorec-
tomy with vena caval thrombectomy has become a safe
treatment in cases of cavoatrial tumor thrombosis, with
operative mortality rates ranging from 2.7% to 13% and an
expected 5-year survival ranging from 30% to 72%.5-13
According to Flocks and Robson,14 in stage III of RCC and
adrenal carcinoma, local node involvement is more likely to
occur. According to these considerations, Skinner and co-
workers15 and Libertino and associates3 reported that tumor
thrombus, to whatever degree of extension, without metas-
tasized local nodes or perinephric fat involvement has a
5-year survival rate similar to that for a tumor that remains
inside the renal capsule. Moreover, these tumors (excluding
Wilms tumor) are not responsive to conventional chemo-
therapy or radiotherapy, and therefore surgical treatment
provides the safest and most effective technique for remov-
ing these tumors.
We reviewed the literature of the last 15 years and found
that management consists primarily of resection and that
several different operations have been advocated, depend-
ing on the proximal extent of the tumor thrombus.
When the thrombus is localized within the infrahepatic
IVC, tumor extraction is usually accomplished after proxi-
mal and distal control of the IVC. When the thrombus
extends into the intrahepatic IVC or higher, isolation of the
IVC requires mobilization of the liver with or without the
use of CPB and, in some circumstances, must be accompa-
nied by DHCA (Table 2).15-22 In stage III and IV disease
various surgical approaches have been described. Control of
the IVC must be achieved by clamping, but several prob-
lems must be resolved, such as the abrupt reduction of the
venous return, which could cause severe hypotension,
bleeding from the uncontrolled suprahepatic veins, and ve-
nous hepatic congestion. When using CPB only, it is nec-
essary to clamp the hepatic artery and the porta hepatis, but
these procedures are limited to the period during which the
liver and the kidneys undergo warm ischemia, thus increas-
ing the surgical risk. Skinner and coworkers15 reported an
average warm liver and kidney ischemia time of 14 minutes
with a range from 8 to 20 minutes. Postoperative compli-
cations occurred in 41% to 60% of the patients and included
transient hyperbilirubinemia, renal dysfunction, and respi-
ratory failure. There were also intraoperative complications
TABLE 1. Patient characteristics
Patient no. Age (y) Sex Symptoms Histology Lymph node Metastases Thrombosis site
1 74 M Hematuria RCC – – IVCRA
2 18 F Hematuria RCC – Lung IVCRA
3 59 M Flank pain RCC – – IVCRA
4 10 M Abdominal mass Wilms – – IVC
5 37 M Peripheral edema Adrenal – – IVC
6 58 M Peripheral edema RCC Yes – IVC
7 56 M Hematuria RCC – – IVC
8 63 F Hematuria RCC Yes – IVC
9 68 F Dyspnea RCC Yes Brain, lung IVCRA
10 26 F Dyspnea Adrenal – Lung IVCRA
11 71 M Hematuria RCC Yes Liver IVCRA
12 60 M Flank pain RCC Yes – IVC
13 66 M Peripheral edema RCC – – IVCRA
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with 3 deaths: 2 were due to exsanguination and 1 to a
massive pulmonary tumor embolization. There were 4 other
perioperative deaths caused by sepsis and multiorgan sys-
tem failure, resulting in an operative mortality rate of 13%.
Other authors23 treated this disease with CPB without
DHCA, which allows for a shorter bypass time and a
reduced risk of bleeding but has several disadvantages:
reduced visualization and exposure because of blood and
hepatic congestion; higher risk of embolization; higher risk
of warm hepatic and renal ischemia; hypoxic liver impair-
ment; and acute tubular necrosis. In the study of Tsuji and
coworkers,16 2 patients died during the early postoperative
period because of retrohepatic caval injury and intraopera-
tive pulmonary embolism. In the study of Stewart and
colleagues,20 all patients received blood transfusions (aver-
age of 10 units of blood, 6 units of platelets, and 2 units of
fresh frozen plasma). Serious perioperative morbidity oc-
curred in 3 patients, transient dementia occurred in 2 pa-
tients, and 1 patient required mediastinal reexploration for
postoperative bleeding. In addition, 3 patients had transient
elevation of serum transaminase and bilirubin levels post-
operatively.
Compared with the results of Glazer and Novick18 and
Welz and associates,22 we think that CPB with DHCA has
several advantages. There is a bloodless surgical field with
reduced risk of cellular spreading, pulmonary embolization,
and fatal hemorrhage. There is also reduced risk of warm
renal and hepatic ischemia, reduced risk of incomplete
tumor excision, and optimal visualization of the IVC lumen
and of the RA, and extended retroperitoneal dissection is
unnecessary. Reported disadvantages of DHCA are ex-
tended bypass time as a result of rewarming, postoperative
bleeding and coagulopathy, and increased neurologic risk.
In our study in-hospital mortality was 0%, and postopera-
tive complications appeared in 3 cases: 1 patient underwent
a relaparotomy for major bleeding, and 2 patients required
blood transfusions (3 and 4 units) early in the postoperative
period. There were no neurologic events.
In conclusion, we believe that when there is a renal or
adrenal tumor that interests the IVC, the RA, or both, the
surgical approach is justified because it allows for the im-
mediate palliation of symptoms, removal of a life-threaten-
ing focus of disease, tumoral burden reduction before bio-
logic therapy, and lower risk of coagulopathies or hepatic
dysfunction. Keep in mind that postoperative survival is
closely related to the stage of the disease (but not to the
stage of caval tumor thrombus) at the time of the operation
rather than the operative approach. Our experience suggests
that CPB with DHCA has improved the safety and the
technical efficacy of a difficult procedure, even in cases of
metastasis providing good perioperative results in terms of
complications, and early and long-term survival.
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